Share Capital (Tables)
|
6 Months Ended |
Jun. 30, 2022 |
|---|
| Equity [Abstract] |
|
| Summary Of Warrants Activity |
The following table summarizes certain information in respect of the Company’s warrants:
|
|
|
|
|
|
|
|
|
| |
|
|
|
| |
|
|
|
|
Weighted Average Exercise Price
(C$) |
|
| Warrants outstanding, beginning |
|
|
22,640 |
|
|
$ |
3.56 |
|
| Granted |
|
|
— |
|
|
|
— |
|
| Forfeited |
|
|
(17,955 |
) |
|
|
2.52 |
|
| Expired |
|
|
(4,685 |
) |
|
|
7.53 |
|
| |
|
|
|
|
|
|
|
|
| Warrants outstanding, ending |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
| Summary Of Assumptions Used To Record Fair Value of Warrants |
As of June 30, 2022 and December 31, 2021, warrants classified as derivative liabilities on the unaudited interim condensed consolidated balance sheets were revalued with the following inputs:
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
| Risk-free interest rate |
|
|
— |
|
|
|
0.9 |
% |
| Expected dividend yield |
|
|
— |
|
|
|
0.0 |
% |
| Expected volatility |
|
|
— |
|
|
|
93.7 - 297.1 |
% |
| Expected life |
|
|
— |
|
|
|
0.9 years |
|
|
| Schedule Of Warrants Outstanding |
Full share equivalent warrants outstanding and exercisable are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
Weighted Average
Exercise Price (C$) |
|
|
|
|
|
Weighted Average
Exercise Price (C$) |
|
| 2022 |
|
|
— |
|
|
|
— |
|
|
|
20,855 |
|
|
|
3.47 |
|
| 2023 |
|
|
— |
|
|
|
— |
|
|
|
1,785 |
|
|
|
4.57 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Summary Of Potentially Dilutive Securities |
The following table summarizes potentially dilutive securities, and the resulting common share equivalents outstanding as of June 30, 2022 and December 31, 2021:
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
| Common share options |
|
|
— |
|
|
|
10,504 |
|
| |
|
|
320,165 |
|
|
|
— |
|
| Warrants |
|
|
— |
|
|
|
22,640 |
|
| Secured notes |
|
|
— |
|
|
|
46,458 |
|
| Debentures |
|
|
— |
|
|
|
10,135 |
|
MPX dilutive instruments (1)
|
|
|
408 |
|
|
|
408 |
|
| |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
(1) |
Prior to the acquisition of MPX Bioceutical Corporation (“MPX”) on February 5, 2019 (the “MPX Acquisition”), MPX had instruments outstanding that were potentially dilutive and as a result of the MPX Acquisition, the Company assumed certain of these instruments. |
|
| Summary Of Option Activity |
The following table summarizes certain information in respect of option activity during the period:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
Weighted
Average
Exercise Price
(C$) |
|
|
Weighted
Average
Contractual
Life |
|
|
|
|
|
Weighted
Average
Exercise Price
(C$) |
|
|
Weighted
Average
Contractual
Life |
|
| Options outstanding, beginning |
|
|
10,504 |
|
|
$ |
4.95 |
|
|
|
— |
|
|
|
11,510 |
|
|
$ |
4.86 |
|
|
|
— |
|
| Granted |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
| Exercised |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
| Cancellations |
|
|
(7,111 |
) |
|
|
4.70 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
| Forfeitures |
|
|
(3,152 |
) |
|
|
5.85 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
| Expirations |
|
|
(241 |
) |
|
|
1.21 |
|
|
|
— |
|
|
|
(1,006 |
) |
|
|
3.96 |
|
|
|
— |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Options outstanding, ending |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Summary Of Restricted Stock Units Activity |
The following table summarizes certain information in respect of RSU activity during the period:
|
|
|
|
|
|
|
|
|
| |
|
|
|
| |
|
|
|
|
Weighted Average Grant
Price (C$) |
|
| Unvested balance, beginning |
|
|
— |
|
|
$ |
— |
|
| Granted |
|
|
390,802 |
|
|
|
0.12 |
|
| Vested |
|
|
(101,514 |
) |
|
|
0.12 |
|
| Forfeited |
|
|
(70,637 |
) |
|
|
0.12 |
|
| |
|
|
|
|
|
|
|
|
| Unvested balance, ending |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|